Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib +/- Interferon alpha-2a in mRCC
NCT00678288Phase 2Terminated
- Sponsor
- Bayer
- Start
- Apr 2008
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of sorafenib in metastatic renal cell carcinoma (mRCC), sponsored by Bayer. Started Apr 2008; status: terminated.
02
Drugs
sorafenib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT00678288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00678288.